


EURASIAN HEMATOLOGY ONCOLOGY CONGRESS

-SCIENTIFIC PROGRAM-

5 October

HALLS	HEMATOLOGY PROGRAM	
13.00 - 13.10	OPENING REMARKS OF EHOC 2022 - GIUSEPPE SAGLIO - BİROL GÜVENÇ - SERDAR BEDİİ OMAY	
13.10 - 13.40	OPENING LECTURE - Can Immune Therapy Cure AML? - Robert Gale	Chair: Serdar Bedii Omay
	SESSION 1: Low Grade NHLs (Turkey & Macedonia & Croatia & Serbia)	Chairs: Burhan Ferhanoglu - Rajko Kusec
13.40 - 14.00	Chemotherapy-Free Approach in the Treatment of Follicular Lymphoma	Ozan Salim (Virtual)
14.00 - 14.20	How I Treat MALT Lymphomas	Irina Panovska
14.20 - 14.40	How I Treat Nodal and Splenic Marginal Zone Lymphoma?	Tayfur Toptaş
14.40 - 15.00	How I Treat Waldenstrom Disease?	Nebojsa Andjelkovic (Virtual)
15.00 - 15.20	General Discussion Chair: Hüseyin Saffet Beköz	
15.20 - 15.50	SATELLITE SYMPOSIUM Carfilzomib in Relapsed/Refractory Multiple Myeloma Chair: Mehmet Turgut Speaker: Mustafa Çetiner	
		
15.50 - 16.20	COFFEE BREAK	
	SESSION 2 - High-Grade NHLs (Turkey and Azerbaijan)	Chairs: Burhan Ferhanoglu - George Janossy
16.20 - 16.40	Treatment of R/R DLBCL in Transplant Ineligible Patients	Tayfur Toptaş
16.40 - 17.00	BV Versus Cheq-Point Inhibitors? Which One? When? Why Should Be Perefered?	Murat Özbalak
17.00 - 17.20	Treatment of Mantle Cell Lymphoma in Transplant Non-Eligible Patients	Valeh Huseynov
17.20 - 17.40	How I Treat Double-Hit Lymphoma and High Grade B Cell Lymphoma (NOS)?	Carmino De Souza
17.40 - 18.00	General Discussion Chair: Olga Meltem Akay	

	SESSION 3 - SOHO 2022 Updates and Highlights	CHAIRS: Hagop Kantarjian (Virtual) - Mehmet Ali Özcan
18.00 - 18.20	SOHO State of the Art & Next Questions: AML	Hagop Kantarjian (Virtual)
18.20 - 18.40	SOHO State of the Art & Next Questions: ALL	Elias Jabbour (Virtual)
18.40 - 19.00	SOHO State of the Art & Next Questions: MDS	Guillermo Garcia Manero (Virtual)
19.00 - 19.20	SOHO State of the Art & Next Questions: CLL	Susan O'Brien (Virtual)
19.20 - 19.40	General Discussion Chair: Hakan Göker	

6 October

HALLS	HEMATOLOGY PROGRAM	
07.20 - 08.10	ORAL PRESENTATION SESSION 1 Chairs:Ömür Gökmen Sevindik - Demet Çekdemir	
07.20 – 07.30	A RARE Presentation Of Systemic Al Amyloidosis; Pulmonary Al Amyloidosis	Simge Erdem
07.30 – 07.40	Treatment of a Patient Diagnosed with Erdheim Chester’s Disease in Cooperation with Plastic Surgery and Hematology	Simge Erdem
07:40 – 07.50	Coronavirus Anxiety Level and Covid 19 Vaccine Attitude Among Hematological Malignancy Patients	Zeynep Tuğba Güven
07:50 – 08.00	Evaluation of MRD-status in post-induction period in pediatric patients with acute lymphoblastic leukemia	Timur Valiev
	SESSION 4 - MPNs	CHAIRS: Tariq Mughal (Virtual) – Mehmet Yılmaz
08.20 - 08.40	Treatment Landscape in Myelofibrosis	Daniela Cilloni
08.40 - 09.00	Interferons in MPNs	Selami Koçak Toprak
09.00 - 09.20	Moleculer Profiling of MPN	Tariq Mughal (Virtual)
09.20 - 09.40	PV New Guidelines	Tiziano Barbui
09.40 - 10.00	General Discussion Chair: Mehmet Yılmaz	
10.00 - 10.30	COFFEE BREAK	

	SESSION 5 - ALL (ABHH)	CHAIRS: Carmino De Souza - Osman İlhan-José Francisco Comenalli Marques Junior
10.30 - 10.50	Update on ALL Therapy in 2022: How Should Be Treated	Dieter Hoelzer
10.50 - 11.10	Management of Ph-positive and Ph-like ALL in 2022	Robin Foà (Virtual)
11.10 - 11.30	Ph+ ALL in Brazil	Wellington Fernandes da Silva Jr. (Virtual)
11.30 - 11.50	How To Perform Precision Medicine in South America: The Example of ALL	Eduardo Rego (Virtual)
11.50 - 12.10	General Discussion Chair: Pervin Topcuoğlu	
12.10 - 12.40	SATELLITE SYMPOSIUM Polycythemia Vera Treatment with Ruxolitinib Chair: Ayşe Tülin Tuğlular Speaker: Sinem Civriz Bozdağ- Polycythemia Vera Treatment Journey Speaker: Mehmet Hilmi Doğu - Ruxolitinib Experience with Cases  NOVARTIS	
12.40 - 13.40	LUNCH BREAK	
	SESSION 6 - MULTIPLE MYELOMA (Greece and Italy)	CHAIRS: Evangelos Terpos (Virtual) - Claudio Cerchione
13.40 - 13.55	Smoldering Myeloma: To Treat or Not to Treat?	Maria Victoria Mateos (Virtual)
13.55 - 14.10	What is the Optimal Frontline Therapy for High-Risk Myeloma?	Angelo Maiolino
14.10 - 14.25	How I Treat Relapsed/Refractory Multiple Myeloma: Road to the Target Therapy	Claudio Cerchione
14.25 - 14.40	Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent?	Evangelos Terpos (Virtual)
14.40 - 14.55	Prognostic Factors in Multiple Myeloma: Do We Need a New ISS?	Moshe Gatt
14.55 - 15.20	General Discussion Chair: Ayşe Tülin Tuğlular	
	SESSION 7 - CLL (Middle East Societies)	CHAIRS: Ahmad Ibrahim - Sevgi Kalayoğlu Beşışık
15.20 - 15.40	New Insights into CLL Pathogenesis	Carlo Croce
15.40 - 16.00	Firstline Treatment of CLL	Ahmad Ibrahim
16.00 - 16.20	Treatment of R/R CLL	Ahmad Alaskar
16.20 - 16.40	MRD in CLL	Tamar Tadmor
16.40 - 17.00	General Discussion Chair: Erdal Kurtoğlu	


17.00 - 17.30	COFFEE BREAK	
	SESSION 8 - SOHO ITALY	CHAIRS: Claudio Cerchione-Giuseppe Saglio-Seçkin Çağırğan
17.30 - 17.45	SOHO Italy State of the Art & Next Questions: MM	Claudio Cerchione
17.45 - 18.00	SOHO Italy State of the Art & Next Questions: ALL and AML	Giovanni Martinelli (Virtual)
18.00 - 18.15	SOHO Italy Next future: ALL and AML	Daniela Cilloni
18.15 - 18.30	SOHO Italy State of the Art & Next Questions: CML	Giuseppe Saglio
18.30 - 18.45	General Discussion Chair: Şehmus Ertop	
18.45 - 19.35	POSTER PRESENTATIONS SESION Chairs: Vahap Okan - Emin Kaya - Mehmet Ali Uçar	
	An Unusual Ocular Lymphoma, Primary Intravitreal Lymphoma Diagnosed Incidentally	Nur Seda İbili Çetinkaya
	Eculizumab Dose Adjustments During Pregnancies in Paroxysmal Nocturnal Hemoglobinuria: A Single Center Experience.	Semra Aydın
	Evaluation and Management of Thyroid Nodules At a Tertiary Care Pediatric Cancer Center in Turkey	Seda Şahin
	Follow-Up Of Chronic Myeloid Leukemia Patients Whose Tyrosine Kinase Treatment Was Stopped: Case Series	Kemal Fidan
	Glomerular Microangiopathy with Marked Systemic Thrombotic Microangiopathy Shortly After Bortezomib in a Newly Diagnosed Poems Syndrome Patient	Tarık Onur Tiryaki
	Long-Term Outcomes Of Patients Treated with Caplacizumab For Immune-Mediated Thrombotic Thrombocytopenic Purpura (ITTP): The Post-Hercules Study	Özgür Pektaş
	Prevention Can be the Best Tool For Adult T-Cell Leukemia. Updated T-Cell Brazil Project	Carmino De Souza
	Quality of Life in Hematological Patients in the Post-Covid Era	Weronika Lebowa
	Rectal Cancer Distance to the Anal Verge and the T Staging: Magnetic Resonance Imaging Findings	Najat Amar
	Relapsed Mantle Cell Lymphoma with Isolated Central Nervous System Involvement That Treated with Ibrutinib; A Case Report and Literature Review	Pınar Tıglioğlu

Rituximab Induced Lung Disease in a Mantle Cell Lymphoma Patient Receiving Maintenance: Case Presentation	Fehmi Hindilerden
Rituximab-Induced Severe Acute Thrombocytopenia in a Patient with Splenic Marginal Zone Lymphoma	Taha Ulutan Kars
The Diversity of Presentation and Management of Subcutaneous Panniculitis –Like T-Cell Lymphoma with Associated Hemophagocytic Syndrome - Case Series Analysis.	Justyna Jedras
The Relationship Between Ferritin Level and Thrombosis in Patients with Difuse Large B-Cell Lymphoma	Buğra Sağlam
Vitamin B 12 Deficiency Mimicking Thrombotic Microangiopathy: A Case Report	Müzeyyen Aslaner Ak
Is There Any New Prognostic Score For Peripheral T-Cell Lymphoma?	Derviş Murad Akkurt
HBH Disease and Systemic Lupus Erythematosus	Nuray Mammadova
The Successful Major Surgery in a Patient with Inherited FVII Deficiency and a Huge Nasopharyngeal Angiofibroma	Ayşegül Ünüvar
Association of NF-1 and Moyamoya Syndrome : Case Report	Şifa Şahin
Serum Total Oxidant and Antioxidant Status in Children with Cancer	Yasin Yılmaz
Succinate Dehydrogenase Subunit B Deficient Pediatric Gist	Melek Yaman Ortaköylü
Trametinib Experience in A Braf P.N 486 _P490del Mutation Positive Langerhans Cell Histiocytosis	Sevim Gencil Karaaslan

7 October

HALLS	HEMATOLOGY PROGRAM	
07.20 - 08.10	ORAL PRESENTATION SESSION 3 Chair: Şebnem İzmir Güner - Mehmet Sinan Dal	
07.20 – 07.30	Treatment-Free Remission In Patients With Chronic Myeloid Leukemia: Management Approaches	Vasile Musteata (Virtual)
07.30-07.40	Intrapleural Therapy to Disrupt Il-6/Il-8 Juxtactine Signalling to Block Tumor Emt - and to Drive Systemic Anti-Tumor Immunity	Vera Donnenberg
07.40-07.50	Low Incidence of Central Nervous System (CNS) Relapse of Diffuse Large B-Cell Lymphoma Despite Limited Use of Intrathecal Prophylaxis	Aamer Aleem (Virtual)
07.50-08.00	The Acute Lymphoblastic Leukemia of Down Syndrome	Mehmet Sezgin Pepeler
	SESSION 9 - CML (ELN Network)	CHAIRS: Giuseppe Saglio - Mehmet Turgut
08.20 - 08.35	Updates in CML Treatment	Pia Raanani (Virtual)
08.35 - 08.50	Third Line Therapy for Resistant and Intollerante Patients	Andreas Hochhaus (Virtual)
08.50 - 09.05	Molecular Monitoring in CML Patients Who Discontinue the TKI Therapy: Minimum Requirements	Naeem Chaundri
09.05 - 09.20	How to Deal with Comorbidities in CML Patients	Mohamed Yassin (Virtual)
09.20 - 09.35	CML Blast Crises Therapy	Tomasz Sacha (Virtual)
09.35 - 10.00	General Discussion Chair: Deniz Sargin	
10.00 - 10.30	COFFEE BREAK	

	SESSION 10 - PERSPECTIVES OF ALLOTRANSPLANT in MYELOID NEOPLASIAS (ROHS)	CHAIRS: Elena Morzova - Ali Ünal
10.30 - 10.50	Role of AlloHSCt in Therapy of BC CML	Elena Morozova
10.50 - 11.10	Results of HSCT in Primary and Secondary MDS	Nikolay Tsvetkov
11.10 - 11.30	Bridge Therapy with Ruxolitinib Before Allo HSCT in MF Patients	Maria Barabanshikova (Virtual)
11.30 - 11.50	Optimal Time for Allo HSCT in AML	Anna Smirnova
11.50 - 12.10	General Discussion Chair: Mehmet Yılmaz	
12.10 - 12.40	<p style="text-align: center;">SATELLITE SYMPOSIUM On The Way of a Longer OS and a Higher CR, Name of the Hope: XOSPATA Chair: Sevgi Kalayoğlu Beşışık Speaker: Ömür Gökmen Sevindik</p> 	
12.40 - 13.40	LUNCH BREAK	
	SESSION 11 - BONE MARROW TRANSPLANTATION (EBMT)	CHAIRS: Anna Sureda (Virtual) - Nilgün Sayinalp
13.40 - 14.00	Reduced Intense Conditioning for Allogeneic Stem Cell Transplantation in AML	Arnon Nagler (Virtual)
14.00 - 14.20	FLT3 Mutated AML: Prevention and Treatment of Post-Transplant Relapse	Ali Bazarbahchi
14.20 - 14.40	Haploidentical Stem Cell Transplantation in AML; Impact of Graft Versus Host Disease Prophylaxis	Giorgia Battipaglia (Virtual)
14.40 - 15.00	The Role of Second Allogeneic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myelogenous Leukemia	Fabio Ciceri (Virtual)
15.00 - 15.20	General Discussion Chair: Zafer Gülbaş	
	SESSION 12 - AML (SMOP)	CHAIRS: Munira Moosajee - Berksoy Şahin
15.20 - 15.40	The landscape of AML (Non-Transplant)	Munira Moosajee
15.40 - 16.00	Transplant Indications and Strategies in AML	Raheel Iftikhar
16.00 - 16.20	New Vulnerable Targets in AML	Giovanni Martinelli (Virtual)
16.20 - 16.40	Treatment of AML in Elderly and Fragile Patients	Alessandro Isidori
16.40 - 17.00	General Discussion Chair: Orhan Ayyıldız	
17.00 - 17.30	COFFEE BREAK	

17.30 - 18.00	SATELLITE SYMPOSIUM A New Hope in AML Powered by V Topic: Venclyxto Therapy Outcomes in Newly Diagnosed AML Patients Ineligible for Intensive Chemotherapy Chair:Seçkin Çağırğan Speaker: Sinem Civriz Bozdağ		
	SESSION 13 - MDS (Israel Society of Hematology)	CHAIRS: Moshe Mittelman - Mustafa Çetiner	
18.00 - 18.20	MDS 2022: Yesterday - Today and Tomorrow	Moshe Mittelman	
18.20 - 18.40	Has There Been Real Improvements in the Treatment of MDS	Charles Schiffer (Virtual)	
18.40 - 19.00	Hereditary Bone Marrow Failure Syndromes	Drorit Merkel (Virtual)	
19.00 - 19.20	Lessons from the European and Israel National MDS Registry	Galia Stemer	
19.20 - 19.40	Invasive Fungal Infections in MDS Patients	Sesin Kocagöz	
19.40 - 20.00	General Discussion Chair: Mustafa Nuri Yenerel		

8 October

HALLS	HEMATOLOGY PROGRAM	
07.20 - 08.00	ORAL PRESENTATION SESSION 4 Chairs: Güven Yılmaz-Leylagül Kaynar	
07.20-07.30	An Updated of Pioneer Project to Collect Data of T-Cell NHL Patients Among Five Regions of Brazil. T-Cell Brazil Project	Carmino De Souza
07.30-07.40	Updated Progression-Free Survival (Pfs) and Depth of Response in Ikema, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (ISA-KD) Vs KD in Relapsed Multiple Myeloma (MM)	Özgür Pektaş
07.40-07.50	Immunophenotypic Features Of Molecular Subtypes Of Breast Cancer	Svetlana Chulkova (Virtual)
07.50-08.00	Real-Life Study of Bio-Clinical Follow-Up After Bnt162b2 Mrna Covid-19 (BNTVC) Vaccination in 235 Patients (PTS) Including 225 With Hematological Malignancies (HM).	Jean Francois Rossi

	SESSION 14 - PNH AND ANTITHROMBOTIC THERAPY	CHAIRS: Drew Provan - Mehmet Sönmez
08.20 - 08.35	Emerging Data for Cancer Associated Thrombosis	Piera Sivera
08.35 - 08.50	Thrombo-inflamation in MPN's	Alessandro Lucchessi
08.50 - 09.05	Vascular Diseases in PNH	Hanan Hamed
09.05 - 09.20	How Will We Manage ITP After The Pandemic?	Drew Provan
09.20 - 09.35	How We (will) Treat PNH?	Semra Aydın
09.35 - 10.00	General Discussion Chair: Fahri Şahin (Virtual)	
10.00 - 10.30	COFFEE BREAK	
10.30 - 11.00	<p style="text-align: center;">SATELLITE SYMPOSIUM Combination treatments with Imids for Multiple Myeloma patients Chair: Birol Güvenç Speaker: Serdar Bedii Omay</p>  	
	SPECIAL LECTURE	Chairs: Albert Donnenberg - Birol Güvenç
11.00 - 11.30	The Future of Engineered T-Cell Therapeutics	Bruce Levine (Virtual)
	SESSION 15 - CELLULAR THERAPY IN CANCER	Chairs: Nikolay Tupitsyn
11.30 - 11.50	From Allogenic Transplantation to Precision Immune Therapy	Jean Francois Rossi
	CELLULAR THERAPY: CAR T-CELLS IN HEMATOLOGICAL MALIGNANCIES	Chairs: Jean Francois Rossi
11.50 - 12.10	European Experience from Barcelona – In-House Preparation and Clinical Results	Manel Juan (Virtual)
12.10 - 12.30	Chinese Experience Tumor Burden and CAR-T Cell-Derived IL-6: Predictive Value in R/R B-ALL	Wu Depei Suzhou (Virtual)
12.30- 12.50	USA Experience: IN-HOUSE Preparation: Prospects and Problems	Albert Donnenberg
	OTHER MODALITIES OF CELLULAR THERAPY	Chairs: Vera Donnenberg
12.50- 13.10	Intrapleural Therapy To Drive Systemic Anti-Tumor Immunity	Vera Donnenberg

13.10- 13.30	Generating Not Genetically-Modified, Car-Like, NK Cells	Martin Villalba
13.30 - 13.50	Round Table: Present and Future of Cellular Therapy From Bench to Bedside	Chairs: Jean Francois Rossi - Oral Nevruz
13.50 - 14.10	CLOSING REMARKS OF EHOc 2022	